reported that EGFR inhibition in lung cancer cells inactivates ETS1 function by reducing AKT activity, and the sustained inactivation of ETS1 reduces the expression of DUSP6, leading to the abnormal activation of ERK1/2 and the induction of TKI resistance.[65] Thus, the specific role and associated mechanism of ETS1 in modulating the sensitivity of ccRCC to TKIs need to be further studied. The gene discussed is MAPK3; the disease is nonpapillary renal cell carcinoma.